Co-Authors
This is a "connection" page, showing publications co-authored by GARY J WHITMAN and MARION ELIZABETH SCOGGINS.
Connection Strength
2.546
-
Screening Breast Ultrasound Following Tomosynthesis. Acad Radiol. 2022 03; 29(3):348-349.
Score: 0.819
-
Imaging Features Following Breast Explant Surgery: A Pictorial Essay. Diagnostics (Basel). 2023 Jun 26; 13(13).
Score: 0.227
-
Reply to "Additional References Relevant to Preoperative Breast Lesion Localization Techniques". AJR Am J Roentgenol. 2022 03; 218(3):562.
Score: 0.206
-
The Challenging Image-Guided Preoperative Breast Localization: A Modality-Based Approach. AJR Am J Roentgenol. 2022 03; 218(3):423-434.
Score: 0.201
-
Imaging of Noncalcified Ductal Carcinoma In Situ. J Clin Imaging Sci. 2021; 11:34.
Score: 0.197
-
Retained Localization Wire Fragments in the Breast: Long-term Follow-up. Curr Probl Diagn Radiol. 2022 May-Jun; 51(3):313-316.
Score: 0.195
-
Pseudoangiomatous Stromal Hyperplasia of the Breast: Multimodality Review With Pathologic Correlation. Curr Probl Diagn Radiol. 2017 Mar - Apr; 46(2):130-135.
Score: 0.136
-
Multiparametric MRI-based radiomic models for early prediction of response to neoadjuvant systemic therapy in triple-negative breast cancer. Sci Rep. 2024 07 12; 14(1):16073.
Score: 0.061
-
Diffusion Tensor Imaging for Characterizing Changes in Triple-Negative Breast Cancer During Neoadjuvant Systemic Therapy. J Magn Reson Imaging. 2024 Oct; 60(4):1367-1376.
Score: 0.059
-
Predicting pathological complete response to neoadjuvant systemic therapy for triple-negative breast cancers using deep learning on multiparametric MRIs. Annu Int Conf IEEE Eng Med Biol Soc. 2023 07; 2023:1-4.
Score: 0.057
-
Prediction of pathologic complete response to neoadjuvant systemic therapy in triple negative breast cancer using deep learning on multiparametric MRI. Sci Rep. 2023 01 20; 13(1):1171.
Score: 0.055
-
Tumor Immune Microenvironment Changes by Multiplex Immunofluorescence Staining in a Pilot Study of Neoadjuvant Talazoparib for Early-Stage Breast Cancer Patients with a Hereditary BRCA Mutation. Clin Cancer Res. 2022 09 01; 28(17):3669-3676.
Score: 0.054
-
Quantitative Apparent Diffusion Coefficients From Peritumoral Regions as Early Predictors of Response to Neoadjuvant Systemic Therapy in Triple-Negative Breast Cancer. J Magn Reson Imaging. 2022 12; 56(6):1901-1909.
Score: 0.052
-
BI-RADS Ultrasound Lexicon Descriptors and Stromal Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer. Acad Radiol. 2022 01; 29 Suppl 1:S35-S41.
Score: 0.050
-
Early ultrasound evaluation identifies excellent responders to neoadjuvant systemic therapy among patients with triple-negative breast cancer. Cancer. 2021 08 15; 127(16):2880-2887.
Score: 0.049
-
Tumor necrosis by pretreatment breast MRI: association with neoadjuvant systemic therapy (NAST) response in triple-negative breast cancer (TNBC). Breast Cancer Res Treat. 2021 Jan; 185(1):1-12.
Score: 0.047
-
Neoadjuvant Talazoparib for Patients With Operable Breast Cancer With a Germline BRCA Pathogenic Variant. J Clin Oncol. 2020 02 10; 38(5):388-394.
Score: 0.043
-
A feasibility study of neoadjuvant talazoparib for operable breast cancer patients with a germline BRCA mutation demonstrates marked activity. NPJ Breast Cancer. 2017; 3:49.
Score: 0.039